Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 631 to 645 of 729 results for diabet*

  1. Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (IPG787)

    We have moved interventional procedures guidance 787 to become HealthTech guidance 721. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  2. 3C Patch for treating diabetic foot ulcers (MTG66)

    We have moved Medical technologies guidance 66 to become HealthTech guidance 615. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Neuropad for detecting preclinical diabetic peripheral neuropathy (MTG38)

    We have moved Medical technologies guidance 38 to become HealthTech guidance 486. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)

    We have moved Medical technologies guidance 42 to become HealthTech guidance 502. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)

    We have moved Medical technologies guidance 22 to become HealthTech guidance 362. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (IPG518)

    We have moved interventional procedures guidance 518 to become HealthTech guidance 371. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Canagliflozin for treating type 2 diabetes in people 10 to 17 years [ID6352]

    In development Reference number: GID-TA11377 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.    

    Withdrawn guidance

  10. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy (TA271)

    This guidance has been updated and replaced by NICE technology appraisal guidance 301.

    Withdrawn guidance

  11. Type 2 diabetes: lixisenatide (ESNM10)

    This evidence summary has been updated and replaced by NICE advice ESNM26.

    Withdrawn advice

  12. Type 2 diabetes: alogliptin (ESNM20)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Withdrawn advice

  13. Type 1 diabetes: insulin degludec (ESNM24)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Withdrawn advice

  14. Type 2 diabetes: lixisenatide (ESNM26)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Withdrawn advice

  15. Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)

    This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.

    Withdrawn guideline